Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized, double-blind, placebo-controlled trial with open-label extension of selexipag in chronic thromboembolic pulmonary hypertension
CTR20192442Phase 3Terminated
- Sponsor
- Actelion
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of selexipag in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Actelion. Started Dec 2019; status: terminated.
02
Drugs
selexipag
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on CTR20192442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192442.